Literature DB >> 20012700

Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?

Raffaele Lombardi1, Dajana Cuicchi, Carmine Pinto, Francesca Di Fabio, Bruno Iacopino, Stefano Neri, Maria Lucia Tardio, Claudio Ceccarelli, Ferdinando Lecce, Giampaolo Ugolini, Sara Pini, Piergiorgio Di Tullio, Mario Taffurelli, Francesco Minni, Andrea Martoni, Bruno Cola.   

Abstract

BACKGROUND: Preoperative chemoradiotherapy has been widely adopted as the standard of care for stage II-III rectal cancers. However, patients with T3N0 lesions had been shown to have a better prognosis than other categories of locally advanced tumor. Thus, neoadjuvant chemoradiation is likely to be overtreatment in this subgroup of patients. Nevertheless, the low accuracy rate of preoperative staging techniques for detection of node-negative tumors does not allow to check this hypothesis. We analyzed a group of patients with cT3N0 low rectal cancer who underwent neoadjuvant chemoradiotherapy with the purpose of evaluating the incidence of metastatic nodes in the resected specimens.
METHODS: Between January 2002 and February 2008, 100 patients with low rectal cancer underwent clinical staging by means of endorectal ultrasound, computed tomography, positron emission tomography, and magnetic resonance imaging. All patients received preoperative 5-fluorouracil-based chemoradiotherapy and surgical resection with curative aim.
RESULTS: Of 100 patients with locally advanced rectal cancer, 32 were clinically staged as T3N0M0. Pathological analysis showed the presence of lymph node metastases in nine patients (28%) (node-positive group). In the remaining 23 cases, clinical N stage was confirmed at pathology (node-negative group). Node-positive and node-negative groups differ only in the number of ypT3 tumors (P < .01).
CONCLUSIONS: Our results indicate that immediate surgery for patients with cT3N0 rectal cancer represents an undertreatment risk in at least 28% of cases, making necessary the use of postoperative chemoradiotherapy. Preoperative chemoradiotherapy should be the therapy of choice on the grounds of the principle that overtreatment is less hazardous than undertreatment for cT3N0 rectal cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012700     DOI: 10.1245/s10434-009-0796-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

1.  Preoperative chemoradiotherapy for clinically diagnosed T3N0 rectal cancer.

Authors:  In Ja Park; Jee Yeon Kim; Chang Sik Yu; Jong Seok Lee; Seok-Byung Lim; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Jin Cheon Kim
Journal:  Surg Today       Date:  2015-02-25       Impact factor: 2.549

2.  Do all locally advanced rectal cancers require radiation? A review of literature in the modern era.

Authors:  David T Vonk; Lisa J Hazard
Journal:  J Gastrointest Oncol       Date:  2010-09

3.  Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers.

Authors:  Olga A Lavryk; Elena Manilich; Michael A Valente; Arshiya Miriam; Emre Gorgun; Matthew F Kalady; Sherief Shawki; Conor P Delaney; Scott R Steele
Journal:  Int J Colorectal Dis       Date:  2019-11-27       Impact factor: 2.571

4.  Expression and prognostic relevance of tumor carcinoembryonic antigen in stage IB non-small cell lung cancer.

Authors:  Jian Wang; Yun Ma; Zhi-Hua Zhu; Dong-Rong Situ; Yi Hu; Tie-Hua Rong
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

5.  Intermittent clamping of the hepatic pedicle in simultaneous ultrasonography-guided liver resection and colorectal resection with intestinal anastomosis: is it safe?

Authors:  Emilio De Raffele; Mariateresa Mirarchi; Samuele Vaccari; Dajana Cuicchi; Ferdinando Lecce; Barbara Dalla Via; Bruno Cola
Journal:  Int J Colorectal Dis       Date:  2014-09-04       Impact factor: 2.571

6.  Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified: analysis of local recurrence.

Authors:  Se-Jin Baek; Seon-Hahn Kim; Jung-Myun Kwak; Jae-Sung Cho; Jae-Won Shin; Azali Hafiz Yafee Amar; Jin Kim
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

7.  The risk of nodal disease in patients with pathological complete responses after neoadjuvant chemoradiation for rectal cancer: a systematic review, meta-analysis, and meta-regression.

Authors:  Ian Jun Yan Wee; Hai Man Cao; James Chi-Yong Ngu
Journal:  Int J Colorectal Dis       Date:  2019-07-04       Impact factor: 2.571

8.  Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer.

Authors:  Jiří Grim; Miloš Hroch; Hroch Miloš; Jaroslav Chládek; Chládek Jaroslav; Jiří Petera; Petera Jiří; Jiřina Martínková; Martínková Jiřina
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

9.  Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer.

Authors:  Deniz Tural; Fatih Selcukbiricik; Özcan Yıldız; Olgun Elcin; Sibel Erdamar; Sabri Güney; Fuat Demireli; Evin Büyükünal; Süheyla Serdengeçti
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

Review 10.  Treatment of locally advanced rectal cancer: controversies and questions.

Authors:  Atthaphorn Trakarnsanga; Suthinee Ithimakin; Martin R Weiser
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.